Clinical reference Biomarker Directory
Back to directory

Alpha-2-Macroglobulin

Emerging

Alpha-2-macroglobulin is a component of the FibroTest composite panel, a noninvasive alternative to liver biopsy for fibrosis staging.

Also known as Alpha-2-macroglobulin A2M
In plain language

This protein blocks certain enzymes and rises during inflammation. It's one ingredient in a commercial blood test panel that estimates liver scarring without needing a biopsy, combining several different blood markers together into one composite score.

Biomarker & context

Alpha-2-macroglobulin is a broad-spectrum protease inhibitor and acute-phase protein produced mainly by the liver.

What it indicates

It's one of the components in FibroTest/FibroSure, a commercial composite blood panel used as a noninvasive alternative to liver biopsy for staging fibrosis in chronic hepatitis and other liver diseases.

Diagnosis & clinical testing

Measured via serum immunoassay as part of the FibroTest panel, combined mathematically with haptoglobin, bilirubin, GGT, and apolipoprotein A1 (all discussed elsewhere in this biomarker set) to generate a composite fibrosis stage estimate.

Guiding treatment

A FibroTest result suggesting significant fibrosis may prompt closer monitoring, antiviral treatment initiation (in viral hepatitis), or specialist referral, offering a noninvasive alternative to biopsy for many patients, similar in spirit to the FIB-4 index discussed earlier for AST/ALT-based fibrosis assessment.

Clinical significance

Works alongside several other markers (haptoglobin, bilirubin, GGT, ApoA1) as part of a combined fibrosis risk score.

References
  1. General hepatology reference literature on FibroTest/FibroSure composite liver fibrosis panels.